Last updated 9 days ago

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

200 patients around the world
Available in Brazil, Chile
The master protocol is MK-3475-U06. As of Protocol Amendment 5, the Pembrolizumab Plus MK-4830 Plus Paclitaxel/Irinotecan arm and the Pembrolizumab Plus MK-4830 Plus Lenvatinib arm are no longer actively enrolling participants.
Merck Sharp & Dohme LLC
5Research sites
200Patients around the world
This study is for people with
Esophageal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica
Recruiting
Natal, Rio Grande Do Norte, 59075-740
Hospital Nossa Senhora da Conceição
Recruiting
Av. Francisco Trein, 596 – 2º andar - Bairro: Cristo Redentor - CEP 91350-200 - Porto Alegre
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Recruiting
Av. Dr. Arnaldo, 251 - Consolação, São Paulo - SP, 01255-090, Brazil
Clínica Las Condes - Santiago de Chile
Recruiting
Estoril 450, Las Condes
Instituto Oncológico FALP - UIDO
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy